Print this Page
Susan Roethke, CRNP, MSN, AOCN, ANP-BC
Fox Chase Cancer Center
333 Cottman Ave
Philadelphia, PA 19111
Presentations:
Roethke Susan. Abstract: Safety considerations for Temsirolimus (Torisel TM), a novel inhibitor of mammalian target of rapamycin, in the treatment of patients with advanced renal cell carcinoma. Poster presentation at ONS Advanced Practice Nursing Conference, # 23A-2539, 2007;
Overview of major cancers :Prostate Cancer in Core Curriculum Review Course for Oncology Nurses, FCCC Dept of Continuing Nursing education. Annually since 2002;
Symptom Management: Case Studies in Treatment of Prostate Cancer With Radiation. Fox Chase Cancer Center 17th Annual Radiation Oncology Conference for Nurses, Therapists, and Dosimetrists, 2008;
Renal Cell Carcinoma: Case Studies, in: Latest Advances in Oncology Care. Oncology Educational Foundation and Elsevier/Mosby's Oncology Report Live, 2006;
Long term issues facing men with prostate and testicular cancers, in: Cancer Care Along the Continuum: Issues Facing Men. Fox Chase Cancer Center Department of Continuing Nursing Education, 2005.
Nurse Practitioner
Nurse Practitioner
Medical Oncology
Meet other members of the
genitourinary cancer treatment team
Meet other members of the
prostate cancer treatment team
Certifications:
Certified Registered Nurse Practitioner (CRNP);
Oncology Certified Nurse (OCN);
Advanced Oncology Certified Nurse (AOCN);
Adult Nurse Practitioner (ANP)
Medical Education
Temple University, Philadelphia, Pa., Masters of Science in Nursing, 2000
Honors and Awards
Temple University College of Allied Health Sciences, Saunders Award, 2000;
Friends of the Fox Chase Cancer Center Scholarship, 1999;
Sigma Theta Tau International Honor Society of Nursing, Kappa Chi Chapter, 1999;
1995 Special Contributor Award, Fox Chase Cancer Center, 1995
Professional Societies
Oncology Nursing Society;
American Society of Clinical Oncology
Publications
Hudes GR, Nathan F, Haas N, Cornfeld M, Giantonio B, Greenberg R, Gomella L, Litwin S, Ross E, Roethke S, McAleer C. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1997; 15(9): 3156-63;
Roethke SK. Initial assessment and diagnosis. In: Contemporary Issues in Prostate Cancer: A Nursing Perspective (2nd Ed), ed Held-Warmkessel J. Sudbury MA: Jones and Bartlett Publishers, 2006: 79-106.
